Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date March 16, 2022 · Filed March 18, 2022
Section 16 reporting ended · disclosed 2022-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,343 |
Ending reported balance
After 2022-03-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-16 · Exercise / conversion · Acquired 6,000 · Balance 25,845 F1: This reflects the number of restricted stock units that became vested as of March 16, 2022. Row 2 · 2022-03-16 · Tax withholding · Disposed 1,502 · Balance 24,343 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,000 |
Reported balance
After 2022-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-16 · Exercise / conversion · Disposed 6,000 · Balance 6,000 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,829 |
Reported balance
After 2022-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-16 · Grant · Acquired 35,829 · Balance 35,829 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2032-03-16 | Direct | 33,419 |
Reported balance
After 2022-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-16 · Grant · Acquired 33,419 · Balance 33,419 F6: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2022.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2022 Filed Mar 18, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 33,419 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · derivative · entry 5 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,419 Underlying: Common Stock · 33,419 shares Expires 2032-03-16 F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 35,829 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · derivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,829 Underlying: Common Stock · 35,829 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · derivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,502 | $7.97 | $11,970.94 |
DisclosureSEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,343 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 357 | $8.42 | $3,005.94 |
DisclosureSEC source: 0000805928-22-000010 · wf-form4_164513208300927.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,845 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:08 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000010 · wf-form4_164513208300927.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,202 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 1,569 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:23 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000181 · wf-form4_164081298746377.xml · derivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:23 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 286 | $9.74 | $2,785.64 |
DisclosureSEC source: 0000805928-21-000181 · wf-form4_164081298746377.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,452 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:23 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000181 · wf-form4_164081298746377.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000175 · wf-form4_164020715735933.xml · derivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 375 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 95 | $9.24 | $877.80 |
DisclosureSEC source: 0000805928-21-000175 · wf-form4_164020715735933.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,588 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000175 · wf-form4_164020715735933.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 637 | $19.20 | $12,230.40 |
DisclosureSEC source: 0000805928-21-000140 · wf-form4_162689834317764.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,308 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000140 · wf-form4_162689834317764.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,945 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:56 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000066 · wf-form4_161610456846121.xml · derivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:56 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,500 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000066 · wf-form4_161610456846121.xml · derivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 361 | $18.71 | $6,754.31 |
DisclosureSEC source: 0000805928-21-000028 · wf-form4_161368718486832.xml · nonDerivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP, Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,936 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 590 | $18.70 | $11,033.00 |
DisclosureSEC source: 0000805928-21-000028 · wf-form4_161368718486832.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP, Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,116 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000028 · wf-form4_161368718486832.xml · nonDerivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP, Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,297 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000028 · wf-form4_161368718486832.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP, Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,706 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 567 | $17.81 | $10,098.27 |
DisclosureSEC source: 0001179110-20-012285 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,124 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:52 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012285 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,691 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 498 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:38 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 96 | $16.42 | $1,576.32 |
DisclosureSEC source: 0001179110-20-012160 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,893 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 16:38 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012160 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,989 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 3,187 | $3.67 Strike: $3.67 | $11,696.29 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · derivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,187 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 625 | $4.81 Strike: $4.81 | $3,006.25 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · derivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,187 | $3.67 | $11,696.29 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of stock options. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 625 | $4.81 | $3,006.25 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of stock options. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003911 · edgar.xml · derivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 24,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003911 · edgar.xml · derivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 351 | $14.68 | $5,152.68 |
DisclosureSEC source: 0001179110-20-001947 · edgar.xml · nonDerivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,802 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001947 · edgar.xml · nonDerivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 573 | $14.68 | $8,411.64 |
DisclosureSEC source: 0001179110-20-001947 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,972 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001947 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,545 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 183 | $16.73 | $3,061.59 |
DisclosureSEC source: 0001179110-19-013086 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,127 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013086 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| May 17, 2019 Filed May 18, 2019 01:47 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 67,952 | $21.14 | $1,436,593.62 |
DisclosureSEC source: 0001179110-19-006343 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,560 Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 573 | $17.57 | $10,067.61 |
DisclosureSEC source: 0001179110-19-002056 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,512 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2019. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002056 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,085 F1 · shares: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:37 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014324 · edgar.xml · derivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:37 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,500 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001179110-18-014324 · edgar.xml · derivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2028-12-27 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015742 · edgar.xml · derivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 9,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015742 · edgar.xml · derivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 16,829 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 11 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,829 shares Expires 2018-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 4,375 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 10 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 4,375 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 5,313 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 9 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187 Underlying: Common Stock · 5,313 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 1,250 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 8 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires 2023-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 40,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · derivative · entry 7 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 16,829 | $1.07 | $18,007.03 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 6 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.